MCK is set to acquire a controlling stake in PRISM Vision Holdings, aiming to expand its specialty care capabilities and strengthen its leadership in eye health solutions across the United States.

Q3 2025 Earnings Call Transcript February 5, 2025 Operator: Welcome to McKesson’s Third Quarter Fiscal 2025 Earnings ...

Welcome to McKesson's third-quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Rachel Rodriguez, ...

Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being ...

McKesson inked a deal to buy a controlling interest in Prism Vision Holdings, as it also logged higher profit and revenue in its fiscal third quarter. The drug distributor said Wednesday that it ...

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Vitalone confirmed the company raised its adjusted EPS guidance to a range of $32.55 to $32.95 for fiscal 2025, representing 19%-20% year-over-year growth. Management raised full-year guidance for ...

Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95. We are also pleased to announce the ...

McKesson posted adjusted earnings per share of $8.03 for the quarter ended December 31, 2024, missing the analyst consensus of $8.27. Revenue came in at $95.29 billion, up 18% YoY but below the $95.77 ...

Reports Q3 revenue $95.3B, consensus $95.86B. “McKesson (MCK) reported strong third quarter operational results with broad-based Revenue growth ...